NCT05032664

Brief Summary

Behavioral and psychological symptoms of dementia (BPSD) is the most prominent and distressing manifestation for older persons with dementia (PWD) and caregivers. Aromatherapy was a potentially safe and effective non-pharmacological strategy in BPSD management and could provide benefits to PWD and caregivers. In Hong Kong, some Residential Care Homes for the Elderly and day care centres have provided aromatherapy service to the PWD receiving service from them. However, no such service was provided to the community-dwelling PWD living at home, which constitute a larger proportion of dementia population in HK. In addition, there is no clear implementation protocol, or formal training to the family caregivers to deliver aromatherapy to PWD in home-based setting. Therefore, this study aims to develop and evaluate the effectiveness of a home-based family caregiver-delivered aromatherapy programme for the management of BPSD. PWD ≥ 60-year-old, with BPSD symptoms, and living at home, as well as their family caregivers will be recruited. Participants who pass the screening are randomly allocated to intervention or control group. Those in the intervention group receive home-based aromatherapy programme. Those in the control group receive no intervention for 3-week control period, and then receive home-based aromatherapy programme. The outcome measures will be conducted at baseline and after the 3-week intervention/control period by using Chinese versions of Neuropsychiatric Inventory (CNPI), Chinese version of Dementia QoL Measure-Proxy (C-DEMQoL-Proxy), and Chinese version of Zarit Burden Interview (CZBI).

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
176

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Aug 2021

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 18, 2021

Completed
9 days until next milestone

First Submitted

Initial submission to the registry

August 27, 2021

Completed
6 days until next milestone

First Posted

Study publicly available on registry

September 2, 2021

Completed
1.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 30, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 30, 2022

Completed
Last Updated

February 8, 2023

Status Verified

February 1, 2023

Enrollment Period

1.3 years

First QC Date

August 27, 2021

Last Update Submit

February 7, 2023

Conditions

Keywords

BPSDDementiaAromatherapy

Outcome Measures

Primary Outcomes (1)

  • Change of older persons with dementia (PWD)'s severity of BPSD as assessed by CNPI

    Chinese versions of Neuropsychiatric Inventory (CNPI) is used to assess the frequency, severity, and degree of caregiver distress of 12 domains of BPSD symptoms Each domain contains one screening question, followed by 7-9 sub-questions. If the caregivers answered 'yes' or had uncertainties in the screening question, sub-questions will be used to confirm the screening question. After confirmation, the caregivers will be asked to rate the frequency (from 1 = occasionally to 4 = very frequently) and severity (from 1 = mild to 3 = severe) of symptoms, and the degree of caregiver distress (from 0 = no distress to 5 = very severe or extreme) for that domain. The total score of each domain will be calculated by multiplying the frequency by severity. The total score for the severity of BPSD symptoms will be calculated by adding the total scores for each domain; a higher score indicates higher severity of BPSD symptoms.

    baseline, after 3-week intervention/ control period

Secondary Outcomes (3)

  • Change of PWD's quality of life as assessed by C-DEMQoL-Proxy

    baseline, after 3-week intervention/ control period

  • Change of family caregivers' distress as assessed by CNPI

    baseline, after 3-week intervention/ control period

  • Change of family caregivers' burden as assessed by CZBI

    baseline, after 3-week intervention/ control period

Study Arms (2)

Intervention Group

EXPERIMENTAL

Home-based aromatherapy programme

Other: Home-based aromatherapy programme

Control Group

OTHER

Wait-list control

Other: Control Group

Interventions

1 hour individualised face-to-face training to family caregivers, and 3 weeks aromatherapy intervention delivered by family caregivers (aromatherapy inhalation 2 times per day, each for 1 hour, using 2 drops of Lavandula angustifolia essential oil.

Intervention Group

Wait-list control, no intervention for 3 weeks, then provide home-based aromatherapy

Control Group

Eligibility Criteria

Age60 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • The PWD must satisfy the following criteria to be included in the study:
  • years old or above
  • residing at home
  • with a diagnosis of dementia of any type and stage of severity
  • presenting with at least one symptom of BPSD in the previous one month before the study
  • able to communicate in Cantonese or Mandarin
  • The caregivers must satisfy the following criteria to be included in the study:
  • family members, partners, or relatives living with PWD
  • provide unpaid daily care to PWD at home
  • literate in Chinese and able to communicate in Cantonese or Mandarin.

You may not qualify if:

  • PWD and their family caregivers are excluded from the study if either of them have:
  • allergy or discomfort after using Lavender essential oil
  • other neurological or psychological diseases besides BPSD
  • the following conditions: pregnancy, breastfeeding, hypotension, exacerbation of asthma, dyspnoea, epilepsy, or glucose-6-phosphate dehydrogenase deficiency
  • current use of the following drugs: anticoagulant Warfarin, antiplatelet Aspirin, central nervous system depressant, or anticonvulsant
  • hate the smell of Lavender or Lavender essential oil
  • PWD have received aromatherapy in the past one month
  • a change in family caregiver within 1 month before the study or during the study period.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Individual applicants

Hong Kong, Hong Kong

Location

Related Publications (1)

  • Li BSY, Cheung AT, Chow KM, Chan CWH. Effects of a home-based aromatherapy programme for the management of behavioural and psychological symptoms of dementia among older persons with dementia: A randomised controlled trial with process evaluation. Integr Med Res. 2025 Jun;14(2):101113. doi: 10.1016/j.imr.2024.101113. Epub 2024 Dec 2.

MeSH Terms

Conditions

Dementia

Interventions

Control Groups

Condition Hierarchy (Ancestors)

Brain DiseasesCentral Nervous System DiseasesNervous System DiseasesNeurocognitive DisordersMental Disorders

Intervention Hierarchy (Ancestors)

Epidemiologic Research DesignEpidemiologic MethodsInvestigative TechniquesResearch DesignMethods

Study Officials

  • Siu Yin Li

    Chinese University of Hong Kong

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
OTHER
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

August 27, 2021

First Posted

September 2, 2021

Study Start

August 18, 2021

Primary Completion

November 30, 2022

Study Completion

November 30, 2022

Last Updated

February 8, 2023

Record last verified: 2023-02

Data Sharing

IPD Sharing
Will not share

The data contain participants' privacy

Locations